Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

60;

ANA773

  • Planned Phase IIa Study – In late 2010 the Company announced plans to resume development of ANA773 in HCV as a complement to DAAs in potential all oral regimens. The next planned study is a 28-day study of ANA773, in combination with ribavirin in the first cohorts and as triple therapy in combination with ribavirin and a DAA in subsequent cohorts. Anadys intends to conduct this Phase IIa study of ANA773 in Europe and expects that up to approximately 75 patients will participate in the trial, inclusive of the DAA cohorts.  ANA773 is the Company's oral, small-molecule inducer of endogenous interferons that acts via the TLR7 pathway.
  • 2011 Anticipated Milestones – Anadys intends to commence the ANA773 28-day study during the second quarter of 2011 and expects to receive 4 week viral load data for ANA773 plus ribavirin in the fourth quarter of 2011.

  • Financial Results and HighlightsAs of December 31, 2010, Anadys' cash, cash equivalents and securities available-for-sale totaled $38.0 million compared to $20.5 million as of December 31, 2009.  The increase in cash, cash equivalents and securities available-for-sale reflects the receipt of net proceeds of $34.7 million from the Company's completed equity financings in June and October of 2010, partially offset by the Company's cash utilization during the year to fund operations.

    Total operating expenses were $4.5 million for the fourth quarter of 2010, compared to $5.6 million for the fourth quarter of 2009.  Included as a component of operating expenses were non-cash, share-based expenses of $0.3 million and $0.4 million for the fourth quarter of 2010 and 2009, respectively.

    Research and development expenses were $2.8 million for the fourth quarter of 2010, compared to $4.0 million for the fourth quarter of 2009.  Included as an offset to research and development expenses in the fourth quarter of
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/18/2014)... Alanda Software, a leading global ... announced today that a top tier global biopharmaceutical ... solution in both the U.S. and EU markets. ... Data Quality remediation portal, designed to help both ... improve their ability to capture, transmit and receive ...
    (Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, ... that in connection with the acquisition of Durata Therapeutics, ... in connection with the termination of PDL,s credit agreement ... amount outstanding of $40 million, accrued interest, and prepayment ... entered into a structured financing transaction with Durata in ...
    (Date:11/17/2014)... Nov. 17, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today the formation of a Medical Advisory ... the Company as it advances the Phase 3 ... treatment of cutaneous T-cell lymphoma (CTCL), a rare ...
    (Date:11/15/2014)... FL (PRWEB) November 14, 2014 ... scientifically validated physical activity and sleep measurement platform ... improved subject experience along with multiple new channels ... and secondary accelerometer. Equipped with Bluetooth Smart technology, ... capture and mobile data uploads to ActiGraph’s cloud-based ...
    Breaking Biology Technology:Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6ActiGraph Launches GT9X Link Activity Monitor 2
    ... 26 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( ... approved MicroCap Management as the,front-runner of its full ... plan that will provide a launch pad for ... of Biomoda,s Senior Executive,Officers., John Cousins, President ...
    ... SAN MATEO, Calif., Nov. 26 NeurogesX, Inc.,(Nasdaq: ... developing novel,pain management therapies, announced today that it ... at the Lazard Capital Markets Healthcare,Conference in New ... will be presenting and Stephen Ghiglieri, Chief Financial ...
    ... (Nasdaq: LXRX ) today announced that a member ... 19th Annual,Health Care Conference at The Pierre Hotel in ... 8:30 a.m. Eastern Time., A live webcast of ... http://www.lexpharma.com . An archived version of the,webcast will ...
    Cached Biology Technology:Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm. 2NeurogesX to Present at Lazard Capital Markets Healthcare Conference 2NeurogesX to Present at Lazard Capital Markets Healthcare Conference 3Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 2
    (Date:11/5/2014)... Janeiro, Brazil -Individuals show great diversity in their ability ... and females greatly differ in their perceptual evaluation of ... smell tests. , Sex differences in olfactory ... and may be connected to one,s perception of smell, ... Thus, women,s olfactory superiority has been suggested to be ...
    (Date:11/4/2014)... Fla. (November 4, 2014) — Think about the way ... How do neighboring cells know that they are supposed ... how do these tissues find the correct place and ... answering these crucial questions. , In a new study, ... to communicate with their surrounding neighbors, at the head-trunk ...
    (Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
    Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2The inside story: How the brain and skull stay together 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
    ... COMO, ITALY -- Traditionally addressed through hand-weeding and/or herbicide ... in nursery production. Increased labor costs have made hand-weeding ... although herbicides may be effective and less expensive, non-target ... can harm the environment. To address the economic and ...
    ... is pleased to announce a mobile-optimized web interface for ... Journal of Experimental Biology and Disease Models & Mechanisms. ... Biology Open , will also be available as a ... increasing number of our readers want to access journal ...
    ... Li Qian, PhD, has won the Louis N. and ... Investigators from the American Heart Association (AHA), marking the ... Gladstone Institutes researcher has been the recipient. ... a leading and independent biomedical-research organization -- and a ...
    Cached Biology News:Biodegradable mulches successfully control weeds in container-grown arborvitae 2Gladstone scientist receives American Heart Association's Katz prize for cardiovascular research 2
    Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
    Weinreb Linker...
    Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
    Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...
    Biology Products: